https://www.selleckchem.com/pr....oducts/ly3537982.htm
4%. Grade 3 or worse gastrointestinal, urinary and other (vomiting, fatigue, pain) toxicity incidence was 2.2%, 3.8%, and 2.7% respectively. No statistically significant correlation between the prescribed EQD2 and symptom control or toxicity was seen. 1year overall survival was 25.1% (median 5.9months). Absent distant metastases, completion of the intended course of radiotherapy, response to radiotherapy, and receipt of further lines of treatment were independent prognostic factors. Palliative radiotherapy is effective for symptoms of
Like
Comment
Share
